WORLD HEALTH ORGANIZATION

AI in precision medicine market growth driven by drug discovery, diagnostics, and therapeutics. AI tools enable personalized healthcare via advanced data analytics, using models like CNNs, RNNs, GANs, and GNNs. Market segmented into oncology, rare diseases, infectious diseases, neurology, cardiology, hematology, and others, with neurology expected to grow fastest. Drug discovery & development dominates the market due to AI's ability to analyze complex data and speed up targeted therapy discovery. Major players include NVIDIA, Google, Microsoft, IBM, and others, adopting strategies like acquisitions and collaborations to strengthen market presence.

A study on early supported discharge (ESD) for older adults in Ireland found that ESD, delivered by multidisciplinary community intervention teams, significantly reduced length of stay and functional decline without increasing adverse outcomes. Frailty was identified as a predictor of functional decline. The study highlights the potential of ESD to improve patient outcomes and reduce healthcare utilization, aligning with international recommendations for home-based rehabilitation.

Eflornithine + lomustine improved OS and PFS in IDH-mutant grade 3 astrocytoma patients vs. lomustine alone, per STELLAR trial results presented at 2024 SNO Annual Meeting.

Merck & Co's Winrevair (sotatercept-csrk) met primary endpoint in phase 3 ZENITH study, showing significant reduction in PAH morbidity/mortality risk. Independent committee recommends trial stop and open-label extension.

International recruitment of nurses can fill workforce gaps and enhance diversity but risks 'brain drain' and challenges like language barriers. Partnerships with international organizations and educational institutions can streamline pipelines, while balancing local and international recruitment is crucial for a sustainable, diverse workforce.

Researchers at Fraunhofer Institute for Molecular Biology and Applied Ecology IME, in collaboration with partners, are developing protein-based sweeteners using biotechnology to replace sugar in beverages. The sweet-tasting protein brazzein, found in the African plant Pentadiplandra brazzeana, is being optimized for taste and stability. The resulting sugar substitute, X3, is 10,000 times sweeter than table sugar and has a honey-like flavor, offering a low-calorie, sugar-free alternative with potential health benefits.

The esoteric testing market is projected to grow from $29.24 billion in 2023 to $51.62 billion in 2028 at a CAGR of 12.1%, driven by advancements in biotechnology, rising chronic diseases, and demand for early disease detection.

Despite effective vaccines and antivirals, HBV infection remains a global health issue affecting over 254 million people. Newer vaccines like HepB-CpG with adjuvants show higher seroprotection rates, especially in immunocompromised groups and nonresponders to conventional vaccines. The HepB-CpG vaccine, approved in the US and EU, requires fewer doses and offers quicker, more durable protection, making it a preferred option for revaccination and high-risk populations.

Research in HIV is shifting towards PrEP therapies due to vaccine failures; Dr. Jonathan Weber highlights the challenges in HIV vaccine development, including lack of animal models and natural immunity, and predicts future investment will focus on long-acting PrEP due to its cost-effectiveness and transformative potential in preventing transmission.